Amgen's third quarter 2013 revenues increased 10 percent
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) has announced results for the third quarter of 2013. Total revenues increased 10 percent to $4,748 million, with 11 percent product sales growth driven by strong performance across the portfolio, particularly from Neulasta® (pegfilgrastim), Enbrel® (etanercept), Prolia® (denosumab) and XGEVA® (denosumab).
Bristol-Myers Squibb reports third quarter 2013 financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) has reported results for the third quarter of 2013 highlighted by the strong performance of key marketed products such as Yervoy, Orencia and Sprycel, the presentation of important clinical data for its immuno-oncology pipeline, and the presentation of key cardiovascular outcomes data for Onglyza®.
Novartis delivers strong sales performance in third quarter
- Details
- Category: Novartis
Group net sales increased 4% (+6% cc) to USD 14.3 billion in the third quarter, with all divisions contributing to growth in constant currencies. Currency had a negative impact of 2 percentage points, mainly from the weakened yen and weakening emerging market currencies. Excluding the impact of patent expiries, underlying net sales grew 10% in constant currencies.
Amgen acquires Filgrastim franchise rights from Roche In 100 markets
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche ("Roche") to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1, 2014. Roche has held the rights to filgrastim and pegfilgrastim under license from Kirin-Amgen, Inc. (a joint venture between Amgen and Kirin Holdings Co. Limited, of Japan) in Eastern Europe, Latin America, Asia, the Middle East and Africa since 1989.
GSK and Genmab announce submission to US regulatory authorities for Arzerra® (ofatumumab)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) and Genmab A/S (OMX: GEN) have announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for the use of Arzerra® (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy.
Roche posts strong sales growth in the first nine months of 2013
- Details
- Category: Roche
Group sales rose 6% to 34.9 billion Swiss francs in the first nine months of the year due to strong demand for Roche's HER2 breast-cancer treatments, as well as higher sales of Avastin and clinical laboratory products from the Diagnostics Division. For the fifth consecutive year Roche was ranked as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry in the Dow Jones Sustainability Index (DJSI), highlighting the Group's commitment to responsible business practices and the creation of long-term value.
Abbott reports third-quarter 2013 results
- Details
- Category: Abbott
Abbott today announced financial results for the third quarter ended Sept. 30, 2013. Third-quarter 2013 worldwide sales of $5.4 billion increased 4.3 percent on an operational basis, with strong performance in Diagnostics and Medical Devices. The sales disruption in International Nutrition is estimated to have reduced Abbott's total worldwide sales growth by nearly 2 percentage points.
More Pharma News ...
- AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
- AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment
- Novartis launches fully interactive Facebook ‘Retina App’ on World Sight Day to raise awareness of retinal disease
- Roche inaugurates Translational and Clinical Research Center at the Alexandria Center for Life Science in New York City
- Bayer accelerates clinical development of promising new drug candidates
- Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin
- Secukinumab (AIN457) showed superiority over Enbrel®